Update on the Virologic and Immunologic Response to Highly Active Antiretroviral Therapy

Overview

Journal Curr Infect Dis Rep

Specialty Infectious Diseases

Date 2004 Jul 22

PMID 15265462

Citations 6

Authors

Lisa P Jacobson

John P Phair

Traci E Yamashita

Affiliations

Soon will be listed here.

Abstract

Highly active antiretroviral therapy (HAART) delays clinical progression by suppressing viral replication, measured by a substantial reduction in HIV RNA, allowing the immune system to reconstitute, measured in most studies by an increase in CD4 cells. These virologic and immunologic consequences do not occur uniformly among HAART users. Markers of HIV disease stage at the time of HAART initiation are critical determinants of the progression while receiving HAART. In this report, we review studies describing the heterogeneous virologic and immunologic progression after the initiation of HAART, discuss methodologic concerns in the study of the response of biomarkers, and update findings obtained in the Multicenter AIDS Cohort Study, which show that CD4 cell count, history of antiretroviral therapy, and age at the time of initiation are independent determinants of response.

Citing Articles

Proteinuria Is Associated With Increased Risk of Fragility Fracture in Men With or at Risk of HIV Infection.

Gonciulea A, Wang R, Althoff K, Estrella M, Sellmeyer D, Palella F J Acquir Immune Defic Syndr. 2019; 81(3):e85-e91.

PMID: 30939529 PMC: 6565496. DOI: 10.1097/QAI.0000000000002039.

An increased rate of fracture occurs a decade earlier in HIV+ compared with HIV- men.

Gonciulea A, Wang R, Althoff K, Palella F, Lake J, Kingsley L AIDS. 2017; 31(10):1435-1443.

PMID: 28574962 PMC: 5624823. DOI: 10.1097/QAD.0000000000001493.

HIV DYNAMICS AND NATURAL HISTORY STUDIES: JOINT MODELING WITH DOUBLY INTERVAL-CENSORED EVENT TIME AND INFREQUENT LONGITUDINAL DATA.

Su L, Hogan J Ann Appl Stat. 2016; 5(1):400-426.

PMID: 27134691 PMC: 4851349. DOI: 10.1214/10-AOAS391.

Age, comorbidities, and AIDS predict a frailty phenotype in men who have sex with men.

Althoff K, Jacobson L, Cranston R, Detels R, Phair J, Li X J Gerontol A Biol Sci Med Sci. 2013; 69(2):189-98.

PMID: 24127428 PMC: 4038242. DOI: 10.1093/gerona/glt148.

Desquilbet L, Jacobson L, Fried L, Phair J, Jamieson B, Holloway M J Gerontol A Biol Sci Med Sci. 2011; 66(9):1030-8.

PMID: 21719610 PMC: 3156632. DOI: 10.1093/gerona/glr097.

References

Douek D, McFarland R, KEISER P, Gage E, Massey J, Haynes B . Changes in thymic function with age and during the treatment of HIV infection. Nature. 1999; 396(6712):690-5. DOI: 10.1038/25374. View

OBrien T, McDermott D, Ioannidis J, Carrington M, Murphy P, Havlir D . Effect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapy. AIDS. 2000; 14(7):821-6. DOI: 10.1097/00002030-200005050-00008. View

Miller V, Staszewski S, Sabin C, Carlebach A, Rottmann C, Weidmann E . CD4 lymphocyte count as a predictor of the duration of highly active antiretroviral therapy-induced suppression of human immunodeficiency virus load. J Infect Dis. 1999; 180(2):530-3. DOI: 10.1086/314890. View

Yamashita T, Phair J, Munoz A, Margolick J, Detels R, OBrien S . Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study. AIDS. 2001; 15(6):735-46. DOI: 10.1097/00002030-200104130-00009. View

Perno C, Cozzi-Lepri A, Balotta C, Forbici F, Violin M, Bertoli A . Secondary mutations in the protease region of human immunodeficiency virus and virologic failure in drug-naive patients treated with protease inhibitor-based therapy. J Infect Dis. 2001; 184(8):983-91. DOI: 10.1086/323604. View

Phillips A, Staszewski S, Weber R, Kirk O, Francioli P, Miller V . HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA. 2001; 286(20):2560-7. DOI: 10.1001/jama.286.20.2560. View

Bahrani A, Ramaswamy R, Oldfield 3rd E . Effects of virologic rebound on CD4 cell counts. Clin Infect Dis. 2001; 32(8):1231-2. DOI: 10.1086/319755. View

Lathey J, Tierney C, Chang S, DAquila R, Bettendorf D, Alexander H . Associations of CCR5, CCR2, and stromal cell-derived factor 1 genotypes with human immunodeficiency virus disease progression in patients receiving nucleoside therapy. J Infect Dis. 2001; 184(11):1402-11. DOI: 10.1086/324427. View

Le Moing V, Chene G, Carrieri M, Besnier J, Masquelier B, Salamon R . Clinical, biologic, and behavioral predictors of early immunologic and virologic response in HIV-infected patients initiating protease inhibitors. J Acquir Immune Defic Syndr. 2001; 27(4):372-6. DOI: 10.1097/00126334-200108010-00007. View

10.

Kleeberger C, Phair J, Strathdee S, Detels R, Kingsley L, Jacobson L . Determinants of heterogeneous adherence to HIV-antiretroviral therapies in the Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr. 2001; 26(1):82-92. DOI: 10.1097/00126334-200101010-00012. View

11.

Hogg R, Heath K, Yip B, Craib K, OShaughnessy M, Schechter M . Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA. 1998; 279(6):450-4. DOI: 10.1001/jama.279.6.450. View

12.

Tarwater P, Margolick J, Jin J, Phair J, Detels R, Rinaldo C . Increase and plateau of CD4 T-cell counts in the 3(1/2) years after initiation of potent antiretroviral therapy. J Acquir Immune Defic Syndr. 2001; 27(2):168-75. DOI: 10.1097/00126334-200106010-00012. View

13.

Mocroft A, Devereux H, Wilson D, Madge S, Youle M, Tyrer M . Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population. Royal Free Centre for HIV Medicine. AIDS. 2000; 14(11):1545-52. DOI: 10.1097/00002030-200007280-00010. View

14.

Walsh J, Pozniak A, Nelson M, Mandalia S, Gazzard B . Virologic rebound on HAART in the context of low treatment adherence is associated with a low prevalence of antiretroviral drug resistance. J Acquir Immune Defic Syndr. 2002; 30(3):278-87. DOI: 10.1097/00126334-200207010-00003. View

15.

Guerin S, Meyer L, Theodorou I, Boufassa F, Magierowska M, Goujard C . CCR5 delta32 deletion and response to highly active antiretroviral therapy in HIV-1-infected patients. AIDS. 2000; 14(17):2788-90. DOI: 10.1097/00002030-200012010-00020. View

16.

Pakker N, Kroon E, Roos M, Otto S, Hall D, Wit F . Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy. INCAS Study Group. AIDS. 1999; 13(2):203-12. DOI: 10.1097/00002030-199902040-00008. View

17.

Greub G, Ledergerber B, Battegay M, Grob P, Perrin L, Furrer H . Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet. 2000; 356(9244):1800-5. DOI: 10.1016/s0140-6736(00)03232-3. View

18.

Deeks S, Barbour J, Martin J, Swanson M, Grant R . Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. J Infect Dis. 2000; 181(3):946-53. DOI: 10.1086/315334. View

19.

Valdez H, Purvis S, Lederman M, Fillingame M, Zimmerman P . Association of the CCR5delta32 mutation with improved response to antiretroviral therapy. JAMA. 1999; 282(8):734. DOI: 10.1001/jama.282.8.734. View

20.

Goetz M, Boscardin W, Wiley D, Alkasspooles S . Decreased recovery of CD4 lymphocytes in older HIV-infected patients beginning highly active antiretroviral therapy. AIDS. 2001; 15(12):1576-9. DOI: 10.1097/00002030-200108170-00017. View